Mumbai Citiclinic Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-07-2024
- Paid Up Capital ₹ 0.25 M
as on 31-07-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.78 M
as on 31-07-2024
- Revenue 2.66%
(FY 2023)
- Profit -30.87%
(FY 2023)
- Ebitda 80.57%
(FY 2023)
- Net Worth 35.95%
(FY 2023)
- Total Assets 24.53%
(FY 2023)
About Mumbai Citiclinic
The Corporate was formerly known as Avon Medical Centre Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.25 M.
The company currently has active open charges totaling ₹3.78 M.
Kashmira Mashru, Puneet Mashru, Nikita Mashru, and One other member serve as directors at the Company.
- CIN/LLPIN
U85120MH2006PTC162808
- Company No.
162808
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mumbai Citiclinic?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikita Mashru  | Director | 06-Aug-2016 | Current |
| Kashmira Mashru | Director | 23-Jun-2006 | Current |
| Puneet Mashru | Director | 16-Jul-2008 | Current |
| Atul Mashru | Director | 06-Jul-2021 | Current |
Financial Performance of Mumbai Citiclinic.
Mumbai Citiclinic Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.66% increase. The company also saw a substantial fall in profitability, with a 30.87% decrease in profit. The company's net worth Soared by an impressive increase of 35.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mumbai Citiclinic?
In 2023, Mumbai Citiclinic had a promoter holding of 55.00% and a public holding of 45.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Apr 2018 | ₹0.88 M | Open |
Others Creation Date: 01 Sep 2016 | ₹0.53 M | Open |
Icici Bank Limited Creation Date: 02 Jul 2008 | ₹1.28 M | Open |
How Many Employees Work at Mumbai Citiclinic?
Unlock and access historical data on people associated with Mumbai Citiclinic, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mumbai Citiclinic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mumbai Citiclinic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
